SCHEMBL5725824

SCHEMBL5725824

CC(C)c1cnc(NC(=O)[C@@H](C)c2ccc(NC(=O)c3cccnc3)cc2)s1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.68
NPC1 O15118 5/20 0.63
RAB9A P51151 5/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
TP53 P04637 2/20 0.63
CCNE1 P24864 4/20 0.57
CDK5 Q00535 4/20 0.57
ALDH1A1 P00352 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
ROCK2 O75116 1/20 0.51
ROCK1 Q13464 1/20 0.51
CYP2C19 P33261 1/20 0.51
GAA P10253 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 1/20 0.47
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726044 1.00 CDK2 (0.68) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726620 1.00 CDK2 (0.68) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726439 0.89 CDK2 (0.72) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5727149 0.89 CDK2 (0.72) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726414 0.89 CDK2 (0.72) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726641 0.83 CDK2 (0.71) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726781 0.83 CDK2 (0.71) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726342 0.83 CDK2 (0.71) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5481269 0.83 CCNE1 (0.64) CDK2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5726403 0.81 CDK2 (1.00) CDK2SMN1; SMN2CCNE1CDK5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406899-B1 PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2006-11-15 EP claimed
US-20040235919-A1 Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents PFIZER ITALIA S.R.I. (IT) 2004-11-25 US claimed
EP-1406899-A2 PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2004-04-14 EP claimed
WO-2003008365-A2 PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2003-01-30 WO claimed
EP-1724270-A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents Pfizer Italia S.r.l. (IT) 2006-11-22 EP disclosed
EP-1406899-B1 PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2006-11-15 EP disclosed
US-20040235919-A1 Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents PFIZER ITALIA S.R.I. (IT) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235919-A1 Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents CDK2, CDK1, CDKN1A CDK2 1/4885NPC1 4121/4885RAB9A 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.